Kalaris Therapeutics reports $93.5 million in cash reserves, projecting funding through Q4 2027 and key clinical milestones.
Kalaris Therapeutics reported a Q2 GAAP loss of $0.48 per share, matching expectations. The company continues patient dosing in its Phase 1b/2 study of TH103, with preliminary data expected in the first half of 2027.
Cash reserves totaled $93.5 million as of June 30, 2026, sufficient to fund operations into late 2027. Phase 3 clinical trials remain on schedule for initiation by the end of 2027, aligning with prior guidance.